Studies have shown that DCs challenged with glycan functionalized nanoparticles coated with tumour antigen payloads are able to cross present the tumour antigens and activate CD8 T cells initiating a cytotoxic effect against tumours [19]. The gene discussed is CD8A; the disease is neoplasm.